Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran

Hossein Norouzian, Mohammadreza Gholami, Pegah Shakib, Gholamreza Goudarzi, Hamze Ghobadian Diali, and Azam Rezvani

1Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, IR Iran
2Razi Vaccine Serum Research Institute, Virology Department, Karaj, IR Iran
3Deputy of Health Services, Lorestan University of Medical Sciences, Khorramabad, IR Iran

*Corresponding author: Gholamreza Goudarzi, Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, IR Iran. Tel/Fax: +98-6633120133, E-mail: goudarzi.gh@gmail.com

Received 2014 November 15; Revised 2015 March 1; Accepted 2015 March 9.

Abstract

Background: Hepatitis C is an infectious disease caused by blood-borne pathogen, hepatitis C virus (HVC).

Objectives: The purpose of this study was to investigate the prevalence of HVC infection and associated risk factors among addicts in drug treatment centers in Lorestan Province, Iran.

Patients and Methods: A cross-sectional sero-behavioral survey was given to drug addicts in the drug treatment centers of Khorramabad, Lorestan Province, Iran during June 2012 - March 2013. Drug addicts were interviewed using a standard questionnaire including demographic, imprisonment history, and HCV-related risk behavior items. Thereafter, the sera drawn from the participants were tested for anti-HCV antibody (Ab), anti-human immunodeficiency virus (HIV) Ab, and hepatitis B surface antigen (HBsAg).

Results: The mean age of the cohorts was 31.7. Up to 60.2% of drug users had educational levels less than high school, 67.5% were self-employed, and 32.5% were office workers. The mean duration of drug injection was 6.8 years. Statistical analyses indicated that the prevalence of HVC among drug addicts was positively associated with age, past incarceration, drug injection history, the duration of drug use, and tattooing. In addition, 16.23% of volunteers were HVC-positive. Of those infected with HVC, 1.10% was co-infected with HBV, 2.95% were positive for HIV, and 0.36% of HVC-positive cases were infected with all three viruses.

Conclusions: The high prevalence of HCV infection among this group implies a high rate of transmission and exposure to the risk of serious diseases. It is important that the high prevalence of HCV infection be taken into consideration to control further transmission of this infection.

Keywords: Hepatitis C Virus, Prevalence, Risk Factors, Substance Abuse Treatment Centers

1. Background

Hepatitis C is a global health problem. The hepatitis C virus (HVC) is mainly transmitted parenterally or in the course of blood contamination during medical procedures.

Worldwide prevalence rates range from 0.01 to 20%, and the world health organization (WHO) estimates that up to 3% of the world’s population (707 million) have been infected with HVC. In developing countries where resources and facilities may be significantly limited, the prevalence of HVC is higher than in the developed world (1).

Worldwide hepatitis C data show significant prevalence rates in high-risk populations, ranging from 30% to 50%, with injecting drug use being the predominant risk factor (1, 2). In Iran, opiates are the most commonly abused drug type, and it has been estimated that 2.8% of adults ages 15 to 64 are opiate abusers (3). Drug addicts are a high-risk group for acquiring one or more parenterally transmitted infection, such as human immunodeficiency virus (HIV), HCV, hepatitis B virus (HBV), and human T-cell leukemia virus type 1 (HTLV-1) (4).

Identified risk factors for HVC infection include intravenous drug use, exposure to infected blood/blood products, intranasal drug use, and tattooing. High-risk populations in Iran are individuals most at risk for hepatitis C, and include those medically underserved, have a history of IV drug injection, and high-risk behaviors (5-7). The main mode of HVC transmission among injecting drug users (IDUs) is by sharing injection equipment, not limited to needle sharing (8).

Several research studies have also reported that HVC is prevalent among prisoners in Iran (5, 9). Prisoners, as a group with high-risk behaviors, are at a major risk of being infected. HVC is usually more prevalent in incarcerated populations than in the surround-
It is also predicted that prison-based sharing practices could exacerbate levels of HCV infection, given the current situation of IDUs in Iran. The association between HCV infection and a history of being tattooed inside prison has been reported from other countries. HCV infection control is an important public health concern, as the majority of infections do not resolve, but lead to chronic infection.

Therefore, the determination of the distribution and risk factors of HCV infection is important to understand the main methods of HCV transmission, which in turn may assist health organizations to plan better preventive policies. There are limited data on the prevalence and correlates of HIV/HCV/HBV co-infection among addicts in Lorestan, Iran.

2. Objectives

The purpose of this study was to survey addicts upon detention in Lorestan to measure the prevalence of co-infection and characterize the risk factors associated with HCV.

3. Patients and Methods

A cross-sectional study was carried out on 271 volunteers who were selected from among addicts in the drug treatment centers in Khorramabad, Lorestan, Iran to estimate the prevalence of HCV and HIV/HCV, HCV/HBV, and associated risk factors during June 2002 - March 2013. The study included an interview and blood testing. The questionnaire covered demographic characteristics (e.g., age, gender, and marital status) as well as risk factors, including the duration of drug injection, past incarceration, injection drug, tattooing, a history of surgery, a history of blood transfusion, and a history of liver disease. Volunteers could end the interview at any time or refuse to answer any question. After completion of the interview, blood specimens were collected for those who agreed to participate in the blood test. The sera samples were tested for HBsAg, anti-HCV anibody (Ab), and anti-HIV-Ab. HI/HCV, HCV/HBV co-infection, and HIV/HCV/HBV triple infections were defined in our study. All the samples were analyzed using ELISA technique to detect HBsAg (Pishtaz Teb Diagnostics, Iran), HIV-Ab (Wantai, China) and HCV-Ab (Diaplus, Italy) in Razi herbal medicines research center, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran. The EIA procedure was applied according to the Diaplus Inc. catalog guidelines.

3.1. Statistical Analysis

The software SPSS Version 16.0 for Windows (SPSS Inc. Chicago, IL, USA) was used for analysis. Univariate analysis using chi-square or Fisher's exact tests were done to assess the association between infection status and associated risk factors. Differences were considered significant when P < 0.05.

4. Results

4.1. Sociodemographic Characteristics of the Study Participants

A total of 271 drug addicts (265 males and 6 females) participated in the study. As shown in Table 1, the majority of participants were male. Study participants ranged in age from 19 to > 51 years. Their mean age was 31.7 years old. Up to 60.2% of drug users had educational levels less than high school. Furthermore, 67.5% were self-employed, 32.5% were office workers, 93.7% were single, and 6.3% were married. The mean duration of drug injection was 6.8 years.

4.2. Prevalence of HIV, HCV, and HBV Infections

In 20.66% of the tested participants, at least one of the three viral infections was seen (95% confidence interval (CI)). Forty-four out of 271 volunteers (16.23%) were positive for HCV-Ab (95% CI: 40.17, 46.62). Of those infected with HCV, 3 (1.10%) were co-infected with HBV (95% CI: 40.17, 46.62), 8 (2.95%) were positive for HIV, and 1 (0.36%) of HCV-positive cases were infected with all three viruses (95% CI: 40.17, 46.62).

In the current study, HCV (16.23%) is more prevalent than HIV (2.95%) and HBV (1.10%) among all addicts. Detailed results on the prevalence of the three infections in both sexes are shown in Table 1.

4.3. Prevalence of HIV/HCV, HCV/HBV, and HIV/HCV/HBV Co-Infection

The prevalence of HIV/HCV, HCV/HBV, and HIV/HCV/ HBV Co-Infection

The prevalence of HIV/HCV, HCV/HBV, and HIV/HCV/ HBV among volunteers was 2.95%, 1.10%, and 0.36%, respectively (Tables 1 and 2).

Table 1. The Prevalence of HIV, HCV, Past or Current HBV, and Viral Co-Infections Among Addicts in Drug Treatment Centers, by Sex and Source of Sampling in Khorramabad, Lorestan, Iran

|                                | Total | Male | Female |
|--------------------------------|-------|------|--------|
|                                | Tested| Tested| Tested |
| HCV                            | 271   | 265   | 6      |
| Positive Cases                 | 44 (16.23) | 43 (15.86) | 1 (0.36) |
| HIV/HCV                        | 271   | 265   | 6      |
| Positive Cases                 | 8 (2.95) | 8 (2.95) | 0      |
| HCV/HBV                        | 271   | 265   | 6      |
| Positive Cases                 | 3 (1.10) | 3 (1.11) | 0      |
| HIV/HCV/HBV All three viruses  | 271   | 265   | 6      |
| Positive Cases                 | 1 (0.36) | 1 (0.36) | 0      |

aData are presented as No. (%).
Table 2. The Prevalence of HIV, HCV, HBV, and Viral Co-Infections Among Addicts in Drug Treatment Center, Age Groups and Source of Sampling in Khorramabad, Lorestan, Iran

| Age Groups | Number Tested | Positive Cases | HCV Positive Cases | HIV/HCV Positive Cases | HCV/HBV Positive Cases | HIV/HCV/HBV Positive Cases |
|------------|---------------|----------------|-------------------|------------------------|------------------------|--------------------------|
| 19 - 30    | 132           | 18 (6.64)      | 15 (5.3)          | 2 (0.73)               | 0                      | 1 (0.36)                 |
| 31 - 40    | 108           | 32 (11.80)     | 25 (9.22)         | 6 (2.21)               | 1 (0.36)               | 0                        |
| 41 - 50    | 19            | 3 (1.1)        | 3 (1.1)           | 0                      | 0                      | 0                        |
| > 51       | 10            | 3 (1.1)        | 1 (0.36)          | 0                      | 2 (0.73)               | 0                        |
| Total      | 56 (20.66)    | 44 (16.23)     | 8 (2.95)          | 3 (1.1)                | 1 (0.36)               |                          |

aData are presented as No. (%).

Table 3. Behavioral Characteristics and Their Association With HCV and Co-Infection (HBV/HIV) Seropositivity Among Addicts in Drug Treatment Centers in Khorramabad, Lorestan, Iran

| Variables                                      | Total (n = 271) | HCV and Co-Infection (HBV/HIV) Positive 1 (n = 56) |
|------------------------------------------------|-----------------|---------------------------------------------------|
| Marital status                                 |                 |                                                   |
| Single                                         | 254 (93.7)      | 52 (92.9)                                         |
| Married                                        | 17 (6.3)        | 4 (7.1)                                           |
| Education level                                |                 |                                                   |
| Primary school                                | 52 (19.2)       | 13 (23.2)                                         |
| High school                                    | 196 (72.32)     | 39 (69.94)                                        |
| University Degree                              | 23 (8.48)       | 4 (7.1)                                           |
| Occupation                                     |                 |                                                   |
| Self-employed                                  | 183 (67.5)      | 39 (69.6)                                         |
| Office worker                                  | 88 (32.5)       | 17 (30.4)                                         |
| Drugs reported having ever used (local name)   |                 |                                                   |
| Opium (tarjaq)                                 | 16 (5.9)        | 4 (7.1)                                           |
| Heroin                                         | 55 (20.4)       | 10 (17.9)                                         |
| "Crack" (purer form of heroin) and Methamphetamine (crystal) | 22 (8.1) | 3 (5.4)                                           |
| All drugs                                      | 177 (65.6)      | 39 (69.6)                                         |
| Types of consumption                           |                 |                                                   |
| Injection                                      | 16 (5.9)        | 7 (12.5)                                          |
| Inhalational                                   | 7 (2.6)         | 2 (3.6)                                           |
| Smoking                                        | 25 (9.2)        | 2 (3.6)                                           |
| All items                                      | 223 (82.3)      | 45 (80.4)                                         |
| Duration of drug abuse                         |                 |                                                   |
| 1 - 5 years                                    | 43 (15.9)       | 1 (1.8)                                           |
| 6 - 10                                         | 105 (38.7)      | 25 (44.6)                                         |
| 11 - 15                                        | 65 (24.0)       | 13 (23.2)                                         |
| 16 - 20                                        | 38 (14.0)       | 16 (23.2)                                         |
| 20<                                            | 20 (7.4)        | 4 (7.1)                                           |
| Blood transfusion                              |                 |                                                   |
| No                                             | 217 (80.7)      | 46 (82.1)                                         |
| Yes                                            | 52 (19.3)       | 10 (17.9)                                         |
| Past incarceration                              |                 |                                                   |
| No                                             | 106 (39.1)      | 5 (8.9)                                           |
| Yes                                            | 165 (60.9)      | 51 (91.1)                                         |
| History of tattooing                           |                 |                                                   |
| No                                             | 119 (45.1)      | 15 (26.8)                                         |
| Yes                                            | 145 (54.9)      | 41 (73.2)                                         |
| History of surgery                             |                 |                                                   |
| No                                             | 158 (58.5)      | 34 (61.8)                                         |
| Yes                                            | 112 (41.5)      | 21 (38.2)                                         |
| History of liver disease (familial history)    |                 |                                                   |
| No                                             | 187 (67.8)      | 49 (87.5)                                         |
| Yes                                            | 26 (12.2)       | 7 (12.5)                                          |
| History of high risk sexual behaviors          |                 |                                                   |
| No                                             | 159 (58.67)     | 39 (69.64)                                        |
| Yes                                            | 112 (41.32)     | 17 (6.27)                                         |

aData are presented as No. (%).
The HCV prevalence was 60% among incarcerated IDUs. In 2001 in the northwestern province of Zanjan, Iran, the HCV prevalence was 47.7% among 346 drug addict prisoners (13).

The prevalence of HCV varies geographically, both within and between countries. The prevalence of anti-HCV found in this study was high, and to assess the related risk factors among drug abuse centers, prisons, and in communities. It is well known that designing an effective management approach to control the prevalence of HIV, HCV, and HBV is a great challenge for health authorities. Therefore, information from a variety of populations and risk factors among them would be useful in understanding the correlation between these infections and the correlated factors in the transmission of each of them. Our study was conducted to study HCV and co-infections with HIV and HBV and to assess the related risk factors among drug abuse treatment centers in Khorramabad, Lorestan, Iran. In the current study, 16.23% of volunteers were positive for HCV.

In early reports from Tehran by Zali et al. (9), ELISA tests were HCV-positive for 45% of imprisoned IDUs. In 2001 in the northwestern province of Zanjan, Iran, the HCV prevalence was 47.7% among 346 drug addict prisoners (13). The HCV prevalence was 60% among incarcerated IDUs in Mashhad, Iran (15). Kheirandish et al. (16) reported an 80.0% HCV prevalence among male IDUs in detention in Tehran, Iran. Furthermore, about 38% of IDU prisoners in the western province of Hamadan, 52% in Tehran, 64.8% in the southern cities of Bandar Abbas and Roodan, and 88.9% in the northern province of Guilan were HCV Ab-positive, whereas the rate in non-IDUs in prison was much lower (17, 18). In our investigation, we studied some risk factors related to HCV. The age-specific analysis of the subjects suggested that prevalence of drug abuse was significantly higher between 31 to 40 years olds. The mean age was 31.7 years. Other studies in Iran have shown that young age groups are more prone to using drugs (19, 20).

Furthermore, this finding could be due to Iran’s young population. In other countries, this age group is more susceptible to drug consumption. Interestingly, in the present study about 98% of the addicts were male. This could indicate the higher prevalence of high-risk behaviors among men compared to women, demonstrating males’ tendency toward addiction and drug injection in Iran. The male gender was reported as an independent predictive factor for HCV infection in different studies (21, 22). However, some studies have suggested there has been a rising number of female drug users over the past two decades (22). HCV is transmitted through contaminated blood transfusion, surgery, surgical instruments, and dental surgery (23). Some healthcare procedures, i.e., surgical and dental treatments, have recently been indicated as risk factors for acute HCV (24), but there was no significant difference between a history of surgery and HCV infection in this study. No significant difference was found between the HCV infection rate and a history of blood transfusions. The main risk factor for acquiring HCV infection before the routine anti-HCV screening of blood donors was blood transfusion in Iran; we started a blood donor screening program in all Iranian blood transfusion centers in 1996. Prior researchers have shown that the HCV infection rate has significantly reduced since the blood screening (25). The development of tests for surrogate markers for HCV and the screening of blood donors has reduced the risk of HCV transmission to 0.001% per unit of transfused blood in developed countries (26).

In our study, HCV-positive status was significantly associated with intravenous drug use. IDUs constitute one of the most important groups at risk of being infected with HCV since they share contaminated needles and other equipment used in injection, use shooting galleries, use cocaine, engage in unsafe sexual activities, and share shaving equipment. They not only have the highest prevalence of HCV infection, but also constitute a potential reservoir of HCV in the community (6).

However, there are several studies in Iran showing that injected drug use is one of the main factors associated with the prevalence of HCV infection (6, 7). Our study has shown that HCV-positive patients had longstanding drug abuse (addictions); 98.1% of HCV-positive cases had
abused drugs for > 6 years. These findings are concerning two reasons. First, longstanding drug use makes treatment very difficult. Second, long-term opiate use can lead to drug injection as result, which is a sufficient amount of time to be afflicted with different infections transmitted by injection (27). Injecting and needle sharing are believed to be the major risk factors for HIV and HCV infections among IDUs. In addition, we found that individuals with a shorter duration of drug abuse were less likely to be HCV seropositive.

The majority of these volunteers had a prison history, showing that cases with a history of imprisonment are much more likely to inject drugs than IDUs without a history of imprisonment.

Our study corroborates the potential role of incarceration in propagating of HCV. As described in other studies, incarceration can lead to increased sharing of injection equipment due to the scarcity of clean needles and syringes (28). Inconsistent with multiple studies around the world that also find incarceration associated with HCV infection and with the injection-related practices that lead to HCV infection (15, 29). In addition, it is possible for non-injection drug users to be at elevated risk for HCV due to incarceration (30). As matter of fact, the incarceration of non-injecting opioid users can precipitate their change to injection, as smoking opium in jails is difficult to conceal. Thus, incarceration may accelerate HCV transmission among IDUs and among previously non-injecting drug users. Nearly 40% of Iranian prisoners were IDUs, and the prevalence of HCV infection among this population has been reported to be between 38 and 90% (15, 17). In high-risk populations in comparison to the general population, tattooing may increase risk status (5). The association between HCV infection and a history of being tattooed inside prison has been reported in other countries. We also found that a history of tattooing that was an independent risk factor for HCV infection (12-14). In the United States, Samuel et al. (12) reported that the receipt of a tattoo inside prison or jail was associated with both HBV and HCV. In Australia, it was also found that being tattooed was an independent risk factor for being HCV positive among a group of prisoners (31). The risk of tattooing for the transmission of HCV infection has also been reported in earlier studies among IDUs in Iran (9). In a study of prisoners in Zanjani, Iran, Khani et al. (31) reported that tattooing was associated with HCV positivity among prisoners. Another study has shown that tattoos might have a higher risk of HCV infection when given in prison (32).

In our study, most subjects had only a primary/secondary school degree, which can be result of dropping out of high school (73.2%) and 7.1% had university degree. A low educational level and/or low socioeconomic status has also been associated with the prevalence of a number of infectious diseases, but we found no statistical association between HCV and educational level.

In conclusion, these studies showed that risk character-istics, including injected drug use, homosexual sexual practice, tattooing, and the length of incarceration, are among potential correlates of HCV infection among drug addicts in Khorraram, Lorestan, Iran. Continued education of public and healthcare professionals will play an important part in controlling this problem since infections in the community are reported as a risk factor for the acquisition of HBV and HCV.

**Acknowledgments**

Special thanks to Lorestan University of Medical Sciences for their financial support of this study. The authors thank the head and staff of the Razi herbal medicines research center of Lorestan University of Medical Sciences.

**Footnote**

Authors’ Contribution: Study concept and design: Mohammadreza Gholami, Hossein Norouzian, and Gholamreza Goudarzi; analysis and interpretation of data: Hossein Norouzian and Mohammadreza Gholami; drafting of the manuscript: Mohammadreza Gholami; critical revision of the manuscript for important intellectual content: Hossein Norouzian, Azam Rezvani, Gholamreza Goudarzi, Pegah Shabib, and Hamze Ghobadian Diali; statistical analysis: Mohammadreza Gholami and Hossein Norouzian.

**References**

1. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res. 2000;462(2-3):381-93. [PubMed: 10767647]
2. Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000;34(5):431-6. [PubMed: 11015105]
3. Pittcock SJ, Lucchinni CF, Parisi JE, Benarroch EE, Mokri B, Stephan CI, et al. Amphetamine autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96-107. doi: 10.1002/ana.20259. [PubMed: 15984010]
4. Zeldis JB, Jain S, Kuramoto IK, Richards C, Szazama K, Samuels S, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med. 1992;157(3):30-5. [PubMed: 1301662]
5. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamadan–Iran. World J Gastroenterol. 2005;11(26):4085-9. [PubMed: 15986055]
6. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002;17(10):1092-7. [PubMed: 1220870]
7. Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. World J Gastroenterol. 2006;12(30):4848-7. [PubMed: 16917474]
8. Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R. High risk injecting behaviour among injecting from Glasgow: cross sectional community wide surveys 1990-1999. J Epidemiol Community Health. 2001;55(10):766-7. [PubMed: 115566]
9. Zali MR, Aghazadeh R, Norouzzi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iran Med. 2005;8(1):315-9.
10. Shafer RF, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug us-
Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients among active young injection drug users in San Francisco (the "junior"
free world) study. J Urban Health. 2002;79(3):475–84. doi: 10.1111/j.1542-4758.200200447.x. [PubMed: 12612103]

Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005;8(2):84–90.

Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2002;127(3):475–84. [PubMed: 11811881]

Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iranian Med. 2003;6(1):3–4.

Babudieri S, Longo B, Sarlati I, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76(1):311–7. doi: 10.1002/jmv.20375. [PubMed: 15902782]

Rahbar A, Rooholamini S, Khooshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy. 2004;15(2):151–5. doi: 10.1016/j.drugpo.2003.07.001.

Kheirandish P, SeyediNiajagh S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86(6):902–8. doi: 10.1111/j.1526-4050.2009.009393.x. [PubMed: 19844670]

Mohtasham Amiri Z, Rezvani M, Jafari Shakh R, Jafari Shakh A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Gilan province. East Mediterr Health J. 2007;13(2):250–6. [PubMed: 17684445]

Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009;13(3):356–8. doi: 10.3950/S1441-86702009000500008. [PubMed: 20424835]

Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan J Med Sci. 2003;19(3):510.

Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80(1):337–46. doi: 10.1093/jurban/jtg037. [PubMed: 12612033]

Alavian SM, Kabir A, Ahmadi AR, Lankarani KB, Shahbahaei MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253–62. doi: 10.1111/j.1542-4758.2010.00437.x. [PubMed: 20499973]

Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009;49(10):2214–20. doi: 10.1111/j.1537-2995.2009.02245.x. [PubMed: 19527477]

Van Staa A, Harden A. Injection practices in the developing world. Geneva; World Health Organization. 1996.

Mele A, Tosti MI, Marzolini A, Moiraghi A, Ragni P, Gallo G, et al. Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat. 2000;7(1):30–5. [PubMed: 10789490]

Akbari A, Imanieh MH, Karimi M, Tabatabaei HR. Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran. Hepat Mon. 2007;7(2):63–6.

Alavian SM, Fallahian F, Lankarani KB. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepat Mon. 2008;8(1):51–9.

Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006;82 Suppl 1:i180–7. doi: 10.1136/sti.2005.019471. [PubMed: 16715287]

Razaghi EM, Movaghar AR, Green TC, Khooshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006;3:32. doi: 10.1186/1542-4758-3-32. [PubMed: 16545137]

Quaglio G, Lugoboni F, Pajuoso B, Sarti M, Talamini G, Lechi A, et al. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis. 2003;37(1):33–40. doi: 10.1086/375566. [PubMed: 12830406]

Day C, Nasseriramanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J. 2006;3:32. doi: 10.1186/1542-4777-3-32. [PubMed: 16439194]

Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect. 2004;132(3):409–15. [PubMed: 15188710]

Zamani S, Ichikawa S, Nasseriramanesh B, Vaziriann M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18(5):559–63. doi: 10.1016/j.drugpo.2007.02.007. [PubMed: 17854723]